Full Year 2025 EBOS Group Ltd Earnings Call Transcript
Key Points
- Ebos Group Ltd (EBOSF) achieved a 12% revenue growth to $12.3 billion and a 7.5% increase in underlying EBITDA to $585 million, aligning with their guidance.
- The company successfully expanded its pharmacy wholesale network by adding over 320 stores and 34 net new TerryWhite Chemmart (TWC) stores.
- Ebos Group Ltd (EBOSF) maintained a strong focus on cost management, achieving a 20 basis point reduction in operating expenditure.
- The company completed strategic acquisitions, including next-generation pet foods and SVS, enhancing their manufacturing capabilities and market reach.
- Ebos Group Ltd (EBOSF) reported strong cash flow generation, with underlying cash flow before CapEx of $448 million, supporting growth investments and shareholder distributions.
- The loss of the Chemist Warehouse Australia contract negatively impacted statutory results compared to the prior period.
- The competitive environment in the pharmacy wholesale market led to tighter margins, expected to continue into FY '26.
- Animal Care faced headwinds due to consumer cost of living pressures, impacting discretionary spending on premium products.
- The company's leverage ratio remained at 1.9x, reflecting significant investment in long-lived distribution center assets.
- Operating costs increased in the second half of FY '25, presenting challenges in managing growth versus previous periods.
Thank you for standing by, and welcome to the EBOS Group Limited FY '25 Full Year Results Conference Call. (Operator Instructions) I must advise you that this conference is being recorded today, the 27th of August 2025. I would now like to hand the conference over to your speaker today, Mr. Adam Hall, CEO, EBOS Group. Please go ahead, Adam.
(spoken in foreign language) and good morning, everyone. Thank you for joining us for the EBOS Group's FY '25 Results Presentation. I'm Adam Hall, the Chief Executive Officer of EBOS Group, and I'm joined today by Alistair Gray, our Chief Financial Officer; and Martin Krauskopf, our Chief Strategy and Corporate Development Officer.
I'd like to say it's an honor to lead the EBOS team, and I've taken the opportunity to get to visit many of our businesses in Australia, New Zealand and Southeast Asia since joining last month. I'm excited for how EBOS' capabilities are well suited for the opportunities ahead.
Turning to the results. FY '25 was another solid
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
